sifuvirtide (FS-0101) / FusoGen Pharma - LARVOL DELTA

Next-Generation Antiviral Peptides: AI-Driven Design, Translational Delivery Platforms, and Future Therapeutic Directions. (PubMed, Virus Res) - "Translational aspects are addressed by discussing novel delivery systems such as nanoparticles, hydrogels, and intranasal/inhalable formulations, as well as clinical trial examples (like, enfuvirtide (T-20), sifuvirtide, lactoferrin-based formulations, PAC-113). Finally, we explore future directions, including CRISPR- and mRNA-based peptide delivery and synergies with immune checkpoint inhibitors. By combining classical mechanisms with AI-driven design and innovative delivery platforms, this review underscores the potential of AVPs as versatile antiviral agents ready for clinical translation."

Journal • Review • Oncology

In vivo Engineering of HSPCs for HIV Gene Therapy using Helper-Dependent Adenoviral Vectors expressing HIV Fusion Inhibitors (ASGCT 2025) - "To test this, we are evaluating three fusion inhibitors expressed from two promoters (human β-Actin and human ubiquitin-C): i) de-immunized C46-v20, ii) stability-enhanced C34 (Sifuvirtide, C34-SFT), and iii) FDA-approved Enfuvirtide (T20)...To assess its safety, we performed in vivo HSPC transduction in GCSF/AMD3100-mobilized human CD46 transgenic mice...The administration of dexamethasone, MMF, and rapamycin rescued the remaining mice, suggesting inflammatory responses by/to C46-v20...We believe that this strategy will improve the safety and efficacy of HIV therapy. Disease Focus of Abstract:HIV"

Gene therapy • Preclinical • Viral vector • Gene Therapies • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Targeted Protein Degradation • CD34 • CD46 • HMGA2 • MIR126 • UBC

Refolding Dynamics of gp41 from Pre-fusion to Pre-hairpin States During HIV-1 Entry. (PubMed, J Chem Inf Model) - "Moreover, we further explored the drug-resistant mechanism of two C-terminal heptad repeat (CHR) derived gp41 inhibitors, T20 and Sifuvirtide, based on the constructed inhibitor-bound gp41 pre-hairpin complexes...Moreover, we conducted several mutant MD simulations to further investigate the mechanisms of how some drug-resistant mutations might affect the pre-hairpin formation, which in turn prevent the inhibitor recognition. Our findings provide deep structural insights into the molecular mechanisms of the pre-hairpin formation for gp41, which facilitates to guide the future anti-HIV drug design."

Journal • CXCR4